Diagnosing Tardive Dyskinesia from Reglan: Clinical Signs and Evaluation

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Legal Risk

If you or a loved one has developed involuntary movements after taking Reglan, you may be wondering how doctors confirm whether it is tardive dyskinesia. Decades of pharmacovigilance research have established a clear link between metoclopramide and this neurological disorder. This page outlines the clinical signs and diagnostic approaches used to evaluate the concern.

Find Out If You Qualify for Compensation →

Reglan and Tardive Dyskinesia: A Documented Risk

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, Reglan carries a boxed warning regarding tardive dyskinesia (TD), a potentially irreversible serious movement disorder. The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should also be avoided for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal involuntary movements. This effect is dose-dependent and cumulative, with longer exposure increasing risk.

Legal Considerations for Virginia Patients

The adequacy of warnings regarding Reglan and TD is a key consideration for affected patients. The boxed warning explicitly states that Reglan can cause TD and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, many patients may have been prescribed Reglan for extended periods beyond the recommended 12-week limit, particularly for conditions like diabetic gastroparesis where longer-term use may have been considered necessary. The warning also advises immediate discontinuation of Reglan in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the potential for delayed diagnosis due to masking of symptoms by the drug itself complicates timely intervention. For patients in Virginia who have developed TD after using Reglan, settlement-related considerations are important. The statute of limitations for filing a claim in Virginia is typically two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. Given that TD may develop gradually and can be masked by continued use of Reglan, the timeline between exposure and documented harm is critical. Patients should document the duration of Reglan use, cumulative dosage, and the onset of TD symptoms. Medical records confirming a diagnosis of TD, along with evidence of prolonged Reglan use beyond the recommended 12-week period, can support a claim. The boxed warning and prescribing information provide clear evidence that the manufacturer was aware of the risk and that warnings were provided, but the adequacy of those warnings in clinical practice may be questioned if patients were not adequately informed or if the drug was used off-label for extended periods. In summary, Reglan use carries a well-documented risk of TD, with the risk increasing with longer treatment duration and higher cumulative doses. Patients in Virginia who have developed TD after using Reglan should be aware of the statute of limitations and the need to establish a clear timeline between exposure and harm. The boxed warning and prescribing information serve as key evidence in evaluating the adequacy of warnings and potential settlement claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related claims in Virginia?

In Virginia, the statute of limitations for filing a claim related to Reglan-induced tardive dyskinesia is typically two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. Given that TD may develop gradually and can be masked by continued use of Reglan, it is crucial to establish a clear timeline between exposure and harm. Patients should consult with an attorney to ensure their claim is filed within the applicable deadline.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through dopamine receptor blockade in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent abnormal involuntary movements. The risk increases with longer treatment duration and higher cumulative doses. The boxed warning on Reglan explicitly states this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.